Agilent Technologies, Inc. (A) Free Cash Flow (FCF): $1.15B
The free cash flow (FCF) for Agilent Technologies, Inc. (A) is $1.15B. It is below its 12-month average by 8.75% ($1.26B).
A Free Cash Flow (FCF) Chart
A Average Free Cash Flow (FCF) Chart
A Current vs Average Free Cash Flow (FCF) Chart
A Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$1.15B
FREE CASH FLOW (FCF) AVG TTM
$1.26B
FREE CASH FLOW (FCF) AVG 3Y
$1.25B
FREE CASH FLOW (FCF) AVG 5Y
$1.19B
FREE CASH FLOW (FCF) AVG 10Y
$968.45M
FREE CASH FLOW (FCF) AVG 15Y
$926.00M
FREE CASH FLOW (FCF) AVG 20Y
$843.90M
CURRENT VS TTM AVG
-8.75%
CURRENT VS 3Y AVG
-8.21%
CURRENT VS 5Y AVG
-2.89%
CURRENT VS 10Y AVG
+18.95%
CURRENT VS 15Y AVG
+24.41%
CURRENT VS 20Y AVG
+36.51%
FCF Analysis
Free Cash Flow (TTM)
$1.15B
FCF Yield
3.26%
Price/FCF
30.6
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Agilent Technologies, Inc. Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Agilent Technologies, Inc. Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Agilent Technologies, Inc. (A)?
- The free cash flow (FCF) for A stock is $1.15B.
- What is the TTM average free cash flow (FCF) for Agilent Technologies, Inc. (A)?
- The TTM average free cash flow (FCF) for A stock is $1.26B.
- What is the 3Y average free cash flow (FCF) for Agilent Technologies, Inc. (A)?
- The 3Y average free cash flow (FCF) for A stock is $1.25B.
- What is the 5Y average free cash flow (FCF) for Agilent Technologies, Inc. (A)?
- The 5Y average free cash flow (FCF) for A stock is $1.19B.
- What is the 10Y average free cash flow (FCF) for Agilent Technologies, Inc. (A)?
- The 10Y average free cash flow (FCF) for A stock is $968.45M.
- What is the 15Y average free cash flow (FCF) for Agilent Technologies, Inc. (A)?
- The 15Y average free cash flow (FCF) for A stock is $926.00M.
- What is the 20Y average free cash flow (FCF) for Agilent Technologies, Inc. (A)?
- The 20Y average free cash flow (FCF) for A stock is $843.90M.
Agilent Technologies, Inc. Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2025-10-31 | $1.15B |
| 2024-10-31 | $1.37B |
| 2023-10-31 | $1.47B |
| 2022-10-31 | $1.02B |
| 2021-10-31 | $1.30B |
| 2020-10-31 | $802.00M |
| 2019-10-31 | $865.00M |
| 2018-10-31 | $910.00M |
| 2017-10-31 | $713.00M |
| 2016-10-31 | $654.00M |
| 2015-10-31 | $393.00M |
| 2014-10-31 | $506.00M |
| 2013-10-31 | $957.00M |
| 2012-10-31 | $1.03B |
| 2011-10-31 | $1.07B |
| 2010-10-31 | $593.00M |
| 2009-10-31 | $280.00M |
| 2008-10-31 | $602.00M |
| 2007-10-31 | $815.00M |
| 2006-10-31 | $449.00M |
| 2005-10-31 | $760.00M |
| 2004-10-31 | $586.00M |
| 2003-10-31 | $-349.00M |
| 2002-10-31 | $-799.00M |
| 2001-10-31 | $621.00M |
| 2000-10-31 | $14.00M |
| 1999-10-31 | $27.00M |
| 1998-10-31 | $341.00M |
Related Metrics
About Agilent Technologies, Inc.
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Padraig McDonnell